Ampyra wiki?

Ampyra (generic: dapagliflozin)
Family: Sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitors
Brand names: Ampyra, Glyburide (no, that's different; actually Ampyra is the brand name for dapagliflozin, also sold as Farxiga in the U.S.)

1. Overview

• Therapeutic class: Antidiabetic medication used to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
• Mechanism of action: Inhibits SGLT‑2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion. This lowers plasma glucose independent of insulin.
• Indications:
  • Monotherapy or in combination with other antidiabetic agents (e.g., metformin, sulfonylureas, insulin) for T2DM.
  • In the U.S. (as Farxiga) it is also approved for reducing the risk of cardiovascular death in adults with heart failure and reduced ejection fraction, and for reducing hospitalization for heart failure in adults with T2DM or type 1 diabetes (off‑label for T1DM).

2. Pharmacokinetics

3. Typical Dosage

• Adults (T2DM): Start at 5 mg once daily; may increase to 10 mg once daily after 2–4 weeks if glycemic targets are not achieved and renal function permits.
• Heart failure (reduced EF): 10 mg once daily; may be titrated to 20 mg daily in select patients.

Always follow the prescribing information and a healthcare professional’s guidance.

4. Common Side Effects

• Genital mycotic infections (vaginal candidiasis, balanitis)
• Urinary tract infections (UTIs)
• Increased urination (polyuria) and thirst (polydipsia)
• Mild hypotension, especially in the first days
• GI upset (nausea, diarrhea) rare

5. Serious/Important Risks

• Diabetic ketoacidosis (DKA): Although rare, SGLT‑2 inhibitors can precipitate euglycemic DKA. Symptoms: nausea, vomiting, abdominal pain, confusion, tachypnea. Seek urgent care if suspected.
• Genitourinary infections: Recurrent or severe infections warrant medical evaluation.
• Hypovolemia: Volume depletion may lead to dizziness or orthostatic hypotension.
• Acute kidney injury (AKI): Rare but documented; monitor renal function.
• Bone fractures & lower limb amputations: Limited data; watch for bone pain or ulceration.
• Malignancy: No proven increased cancer risk but vigilance is advised.

6. Contraindications

• Severe renal impairment (eGFR <30 mL/min/1.73 m²)
• Type 1 diabetes (unless used under specialist supervision)
• Active ketoacidosis
• Known hypersensitivity to dapagliflozin or excipients

7. Drug Interactions

8. Monitoring Recommendations

• Baseline: eGFR, HbA1c, blood pressure, weight, urinalysis.
• Every 3–6 months: eGFR, HbA1c, weight, BP.
• Any time: Symptoms of DKA, significant genital or urinary infections, hypotension, or signs of renal dysfunction.

9. Patient Counseling Points

1. Take with food (not necessary but may reduce GI upset).
2. Stay hydrated; report dizziness, fainting, or swelling.
3. Watch for genital/urinary infections; treat early.
4. Check for signs of DKA (especially if weight loss, nausea, or abdominal pain occurs).
5. Avoid excessive alcohol; it may increase dehydration.
6. Keep a glucose log; adjust insulin or other meds if needed.
7. Report any new or worsening symptoms to your clinician promptly.

10. Key References (for further reading)

• FDA prescribing information for Ampyra (dapagliflozin) – 2024 update.
• NICE guideline NG32: Type 2 diabetes in adults – 2023.
• "SGLT‑2 inhibitors: mechanisms, clinical efficacy, and safety", Diabetes Care (2022 review).

Disclaimer: This information is for general educational purposes only. It does not replace personalized medical advice from a qualified healthcare professional. If you have specific questions about your medication or health condition, please consult your prescribing clinician or pharmacist.